Article
A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
The pharmacogenomics journal - 1 Feb 2014
Han J-Y, Lee Y-S, Shin E Soon, Hwang J-A, Nam S, Hong S-H, Ghang H Young, Kim J Young, Yoon S Jin, Lee J Soo
Abstract excerpt
We conducted a genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) influencing overall survival (OS) of small-cell lung cancer (SCLC) patients. We prospectively collected blood samples from 139 SCLC patients who participated in phase II studies of irinotecan and cisplatin (IP) chemotherapy as first-line therapy. Among 334 127 SNPs, which passed quality control, seven showed...
Topics
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Camptothecin
- Cisplatin
- Clinical Trials, Phase II as Topic
- Data Interpretation, Statistical
- Disease-Free Survival
- Female
- Genome-Wide Association Study
